Table 2 Clinical features at the time of first serum COMP analysis in 70 patients in the longitudinal study, 60 patients in the cross-sectional study, and 97 patients in the ultrasound study
GrouplcSSc/dcSSc, nAge, yearsDuration, yearsVC, p%DLCO, p%mRss, U/litreCOMP
Limited cross-sectional20/050 (10)3.0 (3.4)104 (13)89 (15)7.3 (7.7)11.0 (3.5)
Diffuse cross-sectional0/1148 (15)2.9 (2.9)104 (20)83 (10)21 (6.3)13.7 (7.3)
Alveolitis cross-sectional17/352 (12)4.7 (8.4)80 (15)62 (24)9.2 (10)12.8 (6.4)
Fibrosis cross-sectional0/953 (15)3.4 (3.4)69 (16)45 (18)28 (13)15.3 (6.3)
Low-longitudinal35/045 (14)4.5 (5.1)92 (15)60 (16)4.5 (2.1)8.9 (2.8)*
High-longitudinal4/3152 (16)3.2 (4.0)84 (22)67 (12)29 (8.0)18.5 (7.3)*
Ultrasound cross-sectional68/2950 (14)0.9 (0.5)84 (19)66 (20)13 (11)13.7 (7.0)
  • Values are mean (SD) unless otherwise stated.

  • *p<0.01 high vs low-longitudinal.

  • COMP, cartilage oligomeric matrix protein; dcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing capacity for carbon monoxide; lcSSc, limited cutaneous systemic sclerosis; mRss, modified Rodnan skin score; p%, percentage of predicted value.